Therefore, the simultaneous application of CXCR1/2 inhibitors and HER2 inhibitors in cancer therapy can inhibit the tumor-promoting activity of TAMs, inhibit the proliferation and migration of CSCs, and improve the overall survival rate of patients with cancer [230,231]. Here, CXCR1 is linked to cancer.